ConductScience.org, home

Paper36765622

Clear Cell Renal Cell Carcinoma: From Biology to Treatment.

Kase AM and 2 others. Cancers (Basel), 2023. Cited by 78 papers, by iCite.

Cite this record

ConductScience Library. Clear Cell Renal Cell Carcinoma: From Biology to Treatment. Papers, record 36765622. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36765622

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clear Cell Renal Cell Carcinoma: From Biology to Treatment.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
78
iCite
Relative citation ratio, by iCite
8.19
iCite
Revised in PubMed
2024-09-12
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kase AMAdam Mhttps://orcid.org/0000-0002-1862-8467
2George DJDaniel J
3Ramalingam SSundhar

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References86

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129860937Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.N Engl J Med2018https://conductscience.org/library/papers/29860937PubMed
220368553Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.J Clin Oncol2010https://conductscience.org/library/papers/20368553PubMed
33055163Interferon therapy of metastatic renal cell cancer.Semin Surg Oncol1988https://conductscience.org/library/papers/3055163PubMed
432306075Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients.Cancer Immunol Immunother2020https://conductscience.org/library/papers/32306075PubMed
5291749Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma.J Natl Cancer Inst1979https://conductscience.org/library/papers/291749PubMed
631371341PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.Clin Cancer Res2019https://conductscience.org/library/papers/31371341PubMed
727974689PD-1 and its ligands are important immune checkpoints in cancer.Oncotarget2017https://conductscience.org/library/papers/27974689PubMed
821436444Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.Science2011https://conductscience.org/library/papers/21436444PubMed
933657295Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.N Engl J Med2021https://conductscience.org/library/papers/33657295PubMed
1031377159Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.Int J Radiat Oncol Biol Phys2019https://conductscience.org/library/papers/31377159PubMed
1126482279Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.Lancet Oncol2015https://conductscience.org/library/papers/26482279PubMed
1214043685SPONTANEOUS REGRESSION OF PULMONARY METASTASES SECONDARY TO CARCINOMA OF KIDNEY.Br J Dis Chest1963https://conductscience.org/library/papers/14043685PubMed
1326406150Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.N Engl J Med2015https://conductscience.org/library/papers/26406150PubMed
1426406148Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.N Engl J Med2015https://conductscience.org/library/papers/26406148PubMed
1525410406Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis.Curr Drug Targets2015https://conductscience.org/library/papers/25410406PubMed
1623964934Pazopanib versus sunitinib in metastatic renal-cell carcinoma.N Engl J Med2013https://conductscience.org/library/papers/23964934PubMed
1730679806Interferons α and β in cancer: therapeutic opportunities from new insights.Nat Rev Drug Discov2019https://conductscience.org/library/papers/30679806PubMed
1833616314Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.N Engl J Med2021https://conductscience.org/library/papers/33616314PubMed
1920100962Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.J Clin Oncol2010https://conductscience.org/library/papers/20100962PubMed
2016985675Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma.Rev Urol2002https://conductscience.org/library/papers/16985675PubMed

See all 86 referencesDownload CSV of references

Cited by64

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 78 citations.

PMIDTitleJournalYearIn PapersSource
42952722FN1 promotes invasion of RCC via YWHAZ-associated signaling with partial involvement of the PI3K-Akt pathway.Front Oncol2026https://conductscience.org/library/papers/42952722PubMed
42914499Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma.ESMO Open2026https://conductscience.org/library/papers/42914499PubMed
42769428Promoter Hypermethylation-Driven NPHS2 Silencing Promotes Immune Escape and Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.Oncol Res2026https://conductscience.org/library/papers/42769428PubMed
42758284Quantitative MRI for World Health Organisation/International Society of Urological Pathology Grading of Renal Cell Carcinoma: a systematic review and diagnostic meta-analysis.Eur Radiol2026https://conductscience.org/library/papers/42758284PubMed
42614232Clinicopathological significance and exploratory prognostic modeling of USP18 and YBX3 expression in clear cell renal cell carcinoma: a retrospective Chinese cohort study.Front Oncol2026https://conductscience.org/library/papers/42614232PubMed
42528652Beyond angiogenesis: integrating ferroptosis and metabolic rewiring for next-generation RCC therapy.Front Oncol2026https://conductscience.org/library/papers/42528652PubMed
42502300Single-Cell and Machine Learning Analyses Identify MYDGF as an Immune-Related Biomarker Associated With the Tumor Microenvironment in Clear Cell Renal Cell Carcinoma.Hum Mutat2026https://conductscience.org/library/papers/42502300PubMed
42449597Chimeric Antigen Receptor-Immune Cell-Based Therapies for Clear Cell Renal Cell Carcinoma: Latest Advancements and Directions.Cancers (Basel)2026https://conductscience.org/library/papers/42449597PubMed
42440216Prospective evaluation of 18F-PSMA-1007 PET/CT in renal masses paired with PSMA immunohistochemistry.Ann Nucl Med2026https://conductscience.org/library/papers/42440216PubMed
42278578From Genes to Proteins: The Indispensable Role of Proteogenomics in Advancing Clear Cell Renal Cell Carcinoma Research.Int J Mol Sci2026https://conductscience.org/library/papers/42278578PubMed
42278450De Novo Lipogenesis in Clear Cell Renal Cell Carcinoma: Mechanistic Insights and Therapeutic Implications.Int J Mol Sci2026https://conductscience.org/library/papers/42278450PubMed
42199341SLC40A1 (iron transporter): mechanistic regulation, role in disease pathogenesis, and prospects for targeted therapy.Front Cell Dev Biol2026https://conductscience.org/library/papers/42199341PubMed
42138077Metastatic tropism of molecularly defined clear-cell renal cell carcinoma clusters.J Clin Invest2026https://conductscience.org/library/papers/42138077PubMed
42111157USP18 promotes clear cell renal cell carcinoma progression by regulating the ubiquitination and stability of YBX3.iScience2026https://conductscience.org/library/papers/42111157PubMed
42004076PIM1 expression is prognostic in clear cell renal cell carcinoma and influenced by an IL-6/JAK/STAT axis.Am J Cancer Res2026https://conductscience.org/library/papers/42004076PubMed
41779200Activation of the PI3K/AKT pathway by EDIL3 induces EMT and promotes tumor progression in clear cell renal cell carcinoma.Mol Genet Genomics2026https://conductscience.org/library/papers/41779200PubMed
41519750Comprehensive analysis of key palmitoylation-modifying enzymes in clear cell renal cell carcinoma: implications for prognosis and therapy.Cancer Cell Int2026https://conductscience.org/library/papers/41519750PubMed
41399267Prognostic and Therapeutic Potential of Nicotinamide N-Methyltransferase and Hypoxia Inducible Lipid Droplet Associated in Clear Cell Renal Cell Carcinoma.J Korean Med Sci2025https://conductscience.org/library/papers/41399267PubMed
41346582R3HDM4 influences kidney renal clear cell carcinoma progression, immune modulation, and potential links to the IGSF8 immune checkpoint.Front Immunol2025https://conductscience.org/library/papers/41346582PubMed
41295556Clinical-Oriented Hierarchical Machine Learning Framework for Early Kidney Tumor Detection and Malignant Subtype Classification.Tomography2025https://conductscience.org/library/papers/41295556PubMed

See all 64 cited byDownload CSV of cited by

Genes41

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AXL558PubTator's text mininghttps://conductscience.org/library/genes/558NCBI Gene
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
BTLA151888PubTator's text mininghttps://conductscience.org/library/genes/151888NCBI Gene
CD24451744PubTator's text mininghttps://conductscience.org/library/genes/51744NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CSF21437PubTator's text mininghttps://conductscience.org/library/genes/1437NCBI Gene
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
CXCL83576PubTator's text mininghttps://conductscience.org/library/genes/3576NCBI Gene
EPAS12034PubTator's text mininghttps://conductscience.org/library/genes/2034NCBI Gene
FGFR12260PubTator's text mininghttps://conductscience.org/library/genes/2260NCBI Gene
FLT12321PubTator's text mininghttps://conductscience.org/library/genes/2321NCBI Gene
FLT32322PubTator's text mininghttps://conductscience.org/library/genes/2322NCBI Gene
FLT42324PubTator's text mininghttps://conductscience.org/library/genes/2324NCBI Gene
HAVCR284868PubTator's text mininghttps://conductscience.org/library/genes/84868NCBI Gene
HIF1A3091PubTator's text mininghttps://conductscience.org/library/genes/3091NCBI Gene
IFNA13439PubTator's text mininghttps://conductscience.org/library/genes/3439NCBI Gene
IFNB13456PubTator's text mininghttps://conductscience.org/library/genes/3456NCBI Gene
IL103586PubTator's text mininghttps://conductscience.org/library/genes/3586NCBI Gene

See all 41 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36765622

GET https://conductscience.org/api/papers/v1/36765622/references?page=2